How Are We Going To Live With Alzheimer's Disease?

被引:8
作者
Karlawish, Jason [1 ]
机构
[1] Univ Penn, Philadelphia, PA 19104 USA
关键词
ASSOCIATION WORKGROUPS; DIAGNOSTIC GUIDELINES; NATIONAL INSTITUTE; RECOMMENDATIONS; DEMENTIA; DECISION; CAPACITY; HEALTH; CAREGIVERS; ABILITY;
D O I
10.1377/hlthaff.2014.0089
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Alzheimer's disease confronts us with an ethical challenge: How do we live with dignity and quality of life in the face of progressive disability and, ultimately, death? Patients' cognitive and decision-making impairments often make them unable to answer this question, and when professionals who provide services for older adults fail to recognize and accommodate these impairments, patients suffer. Patients and their caregivers need a health care system that fosters caregiving so that each will live with dignity and well-being. Another way to answer this question is to discover treatments that prevent disabling cognitive impairments, but this strategy will require expanding the Alzheimer's label to include people who do not have dementia or who are even cognitively normal. Controversies are likely to occur over how best to describe the Alzheimer's problem, measure the value of early diagnosis and treatment, and live with a brain at risk.
引用
收藏
页码:541 / 546
页数:6
相关论文
共 50 条
  • [1] Alzheimer's Disease Neuroimaging Initiative: A decade of progress in Alzheimer's disease Foreword
    Thies, William H.
    ALZHEIMERS & DEMENTIA, 2015, 11 (07) : 727 - 729
  • [2] Heterogeneity of Alzheimer's disease
    Balazs Nora
    Kovacs Tibor
    ORVOSI HETILAP, 2021, 162 (25) : 970 - 977
  • [3] How Accurately Do Patients and Their Care Partners Report Results of Amyloid-β PET Scans for Alzheimer's Disease Assessment?
    James, Hailey J.
    Van Houtven, Courtney Harold
    Lippmann, Steven
    Burke, James R.
    Shepherd-Banigan, Megan
    Belanger, Emmanuelle
    Wetle, Terrie Fox
    Plassman, Brenda L.
    JOURNAL OF ALZHEIMERS DISEASE, 2020, 74 (02) : 625 - 636
  • [4] Imaging markers for Alzheimer disease Which vs how
    Frisoni, Giovanni B.
    Bocchetta, Martina
    Chetelat, Gael
    Rabinovici, Gil D.
    de Leon, Mony J.
    Kaye, Jeffrey
    Reiman, Eric M.
    Scheltens, Philip
    Barkhof, Frederik
    Black, Sandra E.
    Brooks, David J.
    Carrillo, Maria C.
    Fox, Nick C.
    Herholz, Karl
    Nordberg, Agneta
    Jack, Clifford R., Jr.
    Jagust, William J.
    Johnson, Keith A.
    Rowe, Christopher C.
    Sperling, Reisa A.
    Thies, William
    Wahlund, Lars-Olof
    Weiner, Michael W.
    Pasqualetti, Patrizio
    DeCarli, Charles
    NEUROLOGY, 2013, 81 (05) : 487 - 500
  • [5] How Can We Improve Transfer of Outcomes from Randomized Clinical Trials to Clinical Practice with Disease-Modifying Drugs in Alzheimer's Disease?
    Gauthier, S.
    Leuzy, A.
    Rosa-Neto, P.
    NEURODEGENERATIVE DISEASES, 2014, 13 (2-3) : 197 - 199
  • [6] Lecanemab in Early Alzheimer's Disease
    van Dyck, Christopher H.
    Swanson, Chad J.
    Aisen, Paul
    Bateman, Randall J.
    Chen, Christopher
    Gee, Michelle
    Kanekiyo, Michio
    Li, David
    Reyderman, Larisa
    Cohen, Sharon
    Froelich, Lutz
    Katayama, Sadao
    Sabbagh, Marwan
    Vellas, Bruno
    Watson, David
    Dhadda, Shobha
    Irizarry, Michael
    Kramer, Lynn D.
    Iwatsubo, Takeshi
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 388 (01) : 9 - 21
  • [7] Minor Hallucinations in Alzheimer's Disease
    Ruiz, Maria
    Arias, Alfonso
    Sanchez-Llanos, Ernesto
    Gil, Maria Pilar
    Lopez-Ortega, Ricard
    Dakterzada, Faride
    Purroy, Francisco
    Pinol-Ripoll, Gerard
    JOURNAL OF ALZHEIMERS DISEASE, 2018, 64 (02) : 543 - 549
  • [8] Alzheimer's disease What do we mean by Alzheimer's disease?
    Richards, Marcus
    Brayne, Carol
    BRITISH MEDICAL JOURNAL, 2010, 341 : 865 - 867
  • [9] When Alzheimer's disease actually begins - the new criteria for mild cognitive impairment and Alzheimer's disease
    Bartos, Ales
    CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE, 2012, 75 (01) : 108 - 109
  • [10] Aducanumab for the treatment of Alzheimer?s disease
    Tagliapietra, Matteo
    DRUGS OF TODAY, 2022, 58 (10) : 465 - 477